Background/Aims: We report on the rates of hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in 1,313 clients entering heroin-assisted treatment (HAT) in Switzerland from 2003 to 2013. We identify predictors of HCV infection. Methods: Data were collected using questionnaires within 2 weeks of clients' first entry into HAT. Prevalence of HAV, HBV, HCV and HIV was calculated using laboratory test results collected at entry or using reports of older test results. Predictors of HCV status were identified through multiple logistic regression analysis. Results: Results show stable rates of HIV-positive clients and decreasing proportions of HAV- and HBV-infected clients. In 2013, there were 12% (n = 8) HIV-, 20% (n = 12) HAV-, 20% (n = 12) HBV- and 52% HCV- (n = 34) positive clients. Vaccination against HAV and HBV had become more frequent. Predictors of positive HCV status included older age, female gender, earlier year of entry, having spent 1 month or more in detention or prison, use of injected heroin and more years of intravenous use. Conclusion: Our results highlight the fact that efforts to prevent and test for infections and to promote vaccination against HAV and HBV in heroin users need to be continued.

Keywords:
Risk factors, HIV, Hepatitis, Heroin-assisted treatment, Heroin users
1.
Uchtenhagen A: Heroin-assisted treatment in Switzerland: a case study in policy change. Addiction 2010;105:29-37.
2.
Centers for Disease Control and Prevention (CDC): Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR Recomm Rep 2012;61:1-40.
3.
Bundesamt für Gesundheit: Infektionskrankheiten A-Z. http://www.bag.admin.ch/themen/medizin/00682/00684/index.html?lang=de (accessed February 5, 2015).
4.
Bundesamt für Gesundheit, Referenzzentren für blutübertragbare Inkfektionen im Gesundheitsbereich: Prävention blutübertragbarer Krankheiten auf Patienten: Empfehlungen für Personal im Gesundheitswesen mit Hepatitis B-, Hepatitis C- oder HIV-Infektion. Richtlinien und Empfehlungen, 2011, p 1.
5.
Gerlich M, Gschwend P, Uchtenhagen A, Krämer A, Rehm J: Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002. Eur J Epidemiol 2006;21:545-549.
6.
Bundesamt für Gesundheit, Schweizerische Expertengruppe für virale Hepatitis, Schweizerische Arbeitsgruppe für reisemedizinische Beratung, Eidgenössische Kommission für Impffragen: Empfehlungen zur Hepatitis-A-Prävention in der Schweiz. Richtlinien und Empfehlungen, 2007, p 11.
7.
Bruggmann P, Brunner N: Neue Hepatitis-therapien bei Drogenkonsumierenden: wird alles besser? Eine Übersicht über die neuen Medikamente und deren Potential, die Versorgung zu verbessern. Suchtmedizin Forsch und Prax 2014;16:285-288.
8.
Reimer J, Lorenzen J, Baetz B, Fischer B, Rehm J, Haasen C, et al: Multiple viral Hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol 2007;22:80-85.
9.
Maher L, Chant K, Jalaludin B, Sargent P: Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. J Gastroenterol Hepatol 2004;19:1114-1120.
10.
Lamden KH, Kennedy N, Beeching NJ, Lowe D, Morrison CL, Mallinson H, et al: Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. J Infect 1998;37:260-269.
11.
Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK: Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J Infect 2009;58:375-382.
12.
Lidman C, Norden L, Kåberg M, Käll K, Franck J, Aleman S, et al: Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis 2009;41:679-684.
13.
Neaigus A, Gyarmathy VA, Miller M, Frajzyngier V, Zhao M, Friedman SR, et al: Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors. Drug Alcohol Depend 2007;89:234-243.
14.
Backmund M, Meyer K, Wächtler M, Eichenlaub D: Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol 2003;18:563-568.
15.
Gschwend P, Rehm J, Lezzi S, Blättler R, Steffen T, Gutzwiller F, et al: Development of a monitoring system for heroin-assisted substitution treatment in Switzerland. Soz Praventivmed 2002;47:33-38.
16.
Infodrog: Kurzkonzept Nationale Sensibilisierungskampagne HepCH, 2005. http://www.infodrog.ch/txt/evenements/2007/hepch_kurzkonzept.pdf (accessed April 2, 2015).
17.
Hosmer DW, Lemeshow SJ, Sturdivant RX: Applied Logistic Regression. New York, John Wiley & Sons, 2013.
18.
Bundesamt für Statistik (BFS): HIV- und STI-Fallzahlen 2012 : Berichterstattung, Analysen und Trends. Bulletin 2013;22:352-359.
19.
Russmann S, Dowlatshahi EA, Printzen G, Habicht S, Reichen J, Zimmermann H: Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. BMC Gastroenterol 2007;7:5.
20.
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-583.
21.
March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F: Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat 2006;31:203-211.
22.
Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al: Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009;361:777-786.
23.
Pharris A, Wiessing L, Sfetcu O, Hedrich D, Botescu A, Fotiou A, et al: Human immunodeficiency virus in injecting drug users in Europe following a reported increase of cases in Greece and Romania, 2011. Euro Surveill 2011;pii:20032.
24.
McMahon JM, Tortu S: A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoactive Drugs 2003;35:455-460.
25.
Backmund M, Meyer K, Schuetz C, Reimer J: Factors associated with exposure to hepatitis B virus in injection drug users. Drug Alcohol Depend 2006;84:154-159.
26.
Morgenthaler M: Ein Viertel der Häftlinge ist drogenabhängig. Standpunkte, 2006, p 2. http://www.suchtschweiz.ch/fileadmin/user_upload/DocUpload/Standpunkte_2_06.pdf.
27.
Frajzyngier V, Neaigus A, Gyarmathy VA, Miller M, Friedman SR: Gender differences in injection risk behaviors at the first injection episode. Drug Alcohol Depend 2007;89:145-152.
28.
Bennett GA, Velleman RD, Barter G, Bradbury C: Gender differences in sharing injecting equipment by drug users in England. AIDS Care 2000;12:77-87.
29.
Marufu M, Williams H, Hill SL, Tibble J, Verma S: Gender differences in hepatitis C seroprevalence and suboptimal vaccination and hepatology services uptake amongst substance misusers. J Med Virol 2012;84:1737-1743.
30.
Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al: The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014;59:109-120.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.